7 Biotechnology Stocks to Buy Now

by Portfolio Grader | December 4, 2013 12:30 pm

This week, seven biotechnology stocks are improving their overall ratings on Portfolio Grader[1]. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

Durata Therapeutics, Inc. (DRTX[2]) is bumping up its rating from a C (“hold”) to a B (“buy”) this week. In Portfolio Grader’s specific subcategory of Earnings Momentum, DRTX also gets an A. For more information, get Portfolio Grader’s complete analysis of DRTX stock[3].

Regulus Therapeutics Inc. (RGLS[4]) shows solid improvement this week. The company’s rating rises from a C to a B. Regulus Therapeutics focuses on the discovery and development of drugs that target microRNAs to treat various diseases in the United States. For more information, get Portfolio Grader’s complete analysis of RGLS stock[5].

This is a strong week for ARIAD Pharmaceuticals, Inc. (ARIA[6]). The company’s rating climbs to B from the previous week’s C. ARIAD Pharmaceuticals is an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients. For more information, get Portfolio Grader’s complete analysis of ARIA stock[7].

Neurocrine Biosciences, Inc. (NBIX[8]) gets a higher grade this week, advancing from a C last week to a B. Neurocrine Biosciences is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. For more information, get Portfolio Grader’s complete analysis of NBIX stock[9].

Array BioPharma (ARRY[10]) earns a B this week, jumping up from last week’s grade of C. Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. For more information, get Portfolio Grader’s complete analysis of ARRY stock[11].

This week, Celldex Therapeutics, Inc. (CLDX[12]) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). Celldex Therapeutics is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. For more information, get Portfolio Grader’s complete analysis of CLDX stock[13].

Insmed Incorporated (INSM[14]) boosts its rating from a C to a B this week. Insmed develops and commercializes drugs that treat metabolic diseases, endocrine disorders and oncology. For more information, get Portfolio Grader’s complete analysis of INSM stock[15].

Louis Navellier’s proprietary Portfolio Grader[16] stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here[17].

Source URL: https://investorplace.com/2013/12/7-biotechnology-stocks-to-buy-now-drtx-rgls-aria/

---